Canaccord Genuity Reiterates a 'Buy' on Stryker (SYK); CEO Abruptly Departs; Underlying Business Solid
SYK Hot Sheet
Rating Summary:18 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Canaccord Genuity reiterates a 'Buy' on Stryker (NYSE: SYK) price target of $67.50.
Analyst, William J. Plovanic, said, "We reiterate our rating following the unexpected announcement that Stryker CEO and Chairman Steve MacMillan has resigned effective immediately, citing family reasons. While we note the abrupt nature of the departure may have a near-term effect on the company’s shares, we believe fundamentals are solid. Furthermore, we continue to believe the company’s remaining senior leadership, product pipeline and diversification position it well for continued success."
For an analyst ratings summary and ratings history on Stryker click here. For more ratings news on Stryker click here.
Shares of Stryker closed at $54.75 yesterday, with a 52 week range of $43.73-$65.21.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
Analyst, William J. Plovanic, said, "We reiterate our rating following the unexpected announcement that Stryker CEO and Chairman Steve MacMillan has resigned effective immediately, citing family reasons. While we note the abrupt nature of the departure may have a near-term effect on the company’s shares, we believe fundamentals are solid. Furthermore, we continue to believe the company’s remaining senior leadership, product pipeline and diversification position it well for continued success."
For an analyst ratings summary and ratings history on Stryker click here. For more ratings news on Stryker click here.
Shares of Stryker closed at $54.75 yesterday, with a 52 week range of $43.73-$65.21.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Canaccord Genuity Maintains a 'Hold' on Tiffany & Co. (TIF); Cutting PT and Estimates
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
- Needham & Company Maintains a 'Hold' on Teva Pharma (TEVA); Adjusting Estimates
Create E-mail Alert Related Categories
Analyst Comments, Management ChangesRelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
